AbbVie recently reported record 2025 results and outlined a stronger 2026 outlook, while advancing key immunology assets and completing the VOLITE skin quality aesthetics trial to bolster its ...

MedImpact Holdings, Inc. today announced the launch of an unbranded biosimilar to Humira(R) (adalimumab) priced at 95% below the brand-name cost. MedImpact is offering this biosimilar (adalimumab-ryvk ...

MedImpact expands access and affordability across healthcare with a low-cost alternative to one of the most prescribed and expensive biologics in the US MedImpact Holdings, Inc. today announced the ...

The product is priced at 95% below the brand-name cost. Ease of adoption. The product is FDA-designated as interchangeable and supported by innovative prescriber and patient engagement programs to ...

MedImpact Holdings, Inc. today announced the launch of an unbranded biosimilar to Humira® (adalimumab) priced at 95% below the brand-name cost. MedImpact is offering this biosimilar (adalimumab-ryvk), ...

Medscape Dermatology asked Steven R. Feldman, MD, PhD, professor of dermatology at Wake Forest University School of Medicine, Winston-Salem, North Carolina, to share his expertise on the impact ...

CVS Health Inc. (NYSE: CVS) on Thursday said it is taking additional steps to lower prescription drug costs by expanding access to biosimilar medications, announcing new formulary changes that will ...

CVS Caremark will begin offering osteoporosis biosimilars Ospomyv and Stoboclo, as well as generic teriparatide, Bonsity and Tymlos. Like Humira and its biosimilars, Prolia is a specialty drug ...

Alvotech remains my favorite in the biosimilars market, which is expected to reach $151.6 billion by 2033. It already has five approved drugs, including biosimilars of AbbVie's Humira, Johnson & ...

CVS Health reported progress on key affordability and access initiatives, including reduced prior authorization burdens and expanded biosimilar adoption. The company has about half as many medical ...